Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 18Sarcoma 1Gynecologic 1

Conditions

Sarcoma 1573Glioblastoma 512Gliosarcoma 485Osteosarcoma 459Brain Neoplasms 344Gastrointestinal Stromal Tumors 326Central Nervous System Neoplasms 296Neoplasms 291Dendritic Cell Sarcoma, Interdigitating 286Astrocytoma 275Lymphoma 260Bone Neoplasms 245Sarcoma, Ewing 238Breast Neoplasms 238Glioma 237Neuroblastoma 230Rhabdomyosarcoma 227Melanoma 225Precursor Cell Lymphoblastic Leukemia-Lymphoma 218Recurrence 216Lymphoma, Non-Hodgkin 216Burkitt Lymphoma 213Oligodendroglioma 203Ovarian Neoplasms 202Lymphoma, Large B-Cell, Diffuse 187Neoplasm Metastasis 186Lymphoma, Follicular 172Leukemia 164Leukemia, Lymphocytic, Chronic, B-Cell 158Hodgkin Disease 158

Interventions

selurampanel 1Postmortem Imaging 1Magnetic Resonance Spectroscopy 1High-Energy Shock Waves 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenocortical Adenoma × Sarcoma × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡